<DOC>
	<DOCNO>NCT00485836</DOCNO>
	<brief_summary>This Phase III , multicenter , randomize , double-masked , sham injection-controlled study efficacy safety intravitreal ranibizumab compare sham injection patient macular edema secondary central retinal vein occlusion ( CRVO ) ; 392 patient CRVO enrol 95 investigational site United States . The study include treatment period ( 6 month ) observation period ( 6 month ) .</brief_summary>
	<brief_title>A Study Efficacy Safety Ranibizumab Injection Patients With Macular Edema Secondary Central Retinal Vein Occlusion ( CRUISE )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Willingness provide sign Informed Consent Form Age ≥ 18 year For sexually active woman childbearing potential , use appropriate form contraception ( abstinence ) duration study Ability willingness return schedule visit assessment Ocular Inclusion Criterion ( Study Eye ) : Foveal centerinvolved macular edema secondary CRVO BCVA use ETDRS chart 20/40 20/320 ( Snellen equivalent ) Mean central subfield thickness ≥ 250 μm two optical coherence tomography ( OCT ) measurement ( screen [ confirm central reading center ] Day 0 [ confirm evaluate physician ] ) Media clarity , pupillary dilation , participant cooperation sufficient obtain adequate fundus photograph History cerebral vascular accident myocardial infarction within 3 month prior Day 0 History antivascular endothelial growth factor ( VEGF ) treatment fellow eye within 3 month prior Day 0 History systemic antiVEGF proVEGF treatment within 6 month prior Day 0 History allergy fluorescein History allergy ranibizumab injection relate molecule Relevant systemic disease may associate increased systemic VEGF level ( namely , active malignancy ) ; history successfully treated malignancy exclusion criterion . Uncontrolled blood pressure Pregnancy lactation Any condition , opinion investigator , would preclude participation study ( e.g. , chronic alcoholism drug abuse , personality disorder use major tranquilizer , indicate difficulty longterm followup , likelihood survival less 1 year ) Participation investigational trial within 30 day prior Day 0 involve treatment drug ( exclude vitamin mineral ) device receive regulatory approval time study entry Ocular Exclusion Criteria ( Study Eye ) : Prior episode retinal vein occlusion ( RVO ) Brisk afferent pupillary defect History radial optic neurotomy sheathotomy History presence agerelated macular degeneration ( AMD ; dry wet form ) History antiVEGF treatment study eye within 3 month prior Day 0 History laser photocoagulation macular edema within 4 month prior Day 0 History panretinal scatter photocoagulation sector laser photocoagulation within 3 month prior randomization anticipate within next 4 month follow randomization History intraocular corticosteroid use within 3 month prior Day 0 History par plana vitrectomy History intraocular surgery ( include cataract extraction , scleral buckle , etc . ) within 2 month prior Day 0 anticipate within next 7 month follow Day 0 History yttriumaluminumgarnet capsulotomy perform within 2 month prior Day 0 Previous filtration surgery study eye History herpetic ocular infection History ocular toxoplasmosis History rhegmatogenous retinal detachment History idiopathic central serous chorioretinopathy Evidence upon examination vitreoretinal interface disease ( e.g. , vitreomacular traction , epiretinal membrane ) , either clinical examination OCT , think contribute macular edema An eye , investigator 's opinion , would benefit resolution macular edema , eye foveal atrophy , dense pigmentary change , dense subfoveal hard exudate Presence ocular condition , opinion investigator , might affect macular edema alter visual acuity study ( e.g. , uveitis ocular inflammatory disease , neovascular glaucoma , IrvineGass syndrome , prior maculaoff rhegmatogenous retinal detachment ) Visually significant hemorrhage obscure fovea felt major contributor reduce visual acuity Presence substantial cataract , opinion investigator , likely decrease visual acuity 3 line ( i.e. , 20/40 cataract ) Aphakia Relevant ocular disease may associate increase intraocular VEGF level ( namely , uveitis , neovascular glaucoma , neovascular AMD , diabetic retinopathy , diabetic maculopathy , ocular ischemic syndrome ) Improvement &gt; 10 letter best correct visual acuity ( BCVA ) screen Day 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>CRVO</keyword>
	<keyword>RVO</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Edema</keyword>
</DOC>